BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32825929)

  • 1. The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions.
    Vougiouklakis T; Belovarac BJ; Lytle A; Chiriboga L; Ozerdem U
    Pathol Res Pract; 2020 Sep; 216(9):153041. PubMed ID: 32825929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-operative breast pathology: apocrine lesions.
    Wells CA; El-Ayat GA
    J Clin Pathol; 2007 Dec; 60(12):1313-20. PubMed ID: 18042688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
    Celis JE; Moreira JM; Gromova I; Cabezón T; Gromov P; Shen T; Timmermans V; Rank F
    Mol Oncol; 2007 Jun; 1(1):97-119. PubMed ID: 19383289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.
    Asirvatham JR; Falcone MM; Kleer CG
    Arch Pathol Lab Med; 2016 Oct; 140(10):1045-51. PubMed ID: 27684975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.
    Chantzi NI; Palaiologou M; Stylianidou A; Goutas N; Vassilaros S; Kourea HP; Dhimolea E; Mitsiou DJ; Tiniakos DG; Alexis MN
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):1057-66. PubMed ID: 24671226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast.
    D'Arcy C; Quinn C
    J Clin Pathol; 2019 Jan; 72(1):1-6. PubMed ID: 30409840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast.
    Kővári B; Báthori Á; Cserni G
    Pathobiology; 2015; 82(6):259-63. PubMed ID: 26562027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of apocrine proliferations of the breast: a morphologic approach.
    Masood S; Rosa M
    Pathol Res Pract; 2009; 205(3):155-64. PubMed ID: 19147303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Wells CA
    Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Histologic Spectrum of Apocrine Lesions of the Breast.
    Durham JR; Fechner RE
    Am J Clin Pathol; 2000 May; 113(suppl_1):S3-18. PubMed ID: 11993707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.
    Visscher DW
    Arch Pathol Lab Med; 2009 Nov; 133(11):1817-21. PubMed ID: 19886717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.
    Tramm T; Kim JY; Leibl S; Moinfar F; Tavassoli FA
    Virchows Arch; 2016 Sep; 469(3):285-95. PubMed ID: 27287269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
    Kunju LP; Kleer CG
    Hum Pathol; 2007 Jan; 38(1):35-41. PubMed ID: 17095049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
    Celis JE; Cabezón T; Moreira JM; Gromov P; Gromova I; Timmermans-Wielenga V; Iwase T; Akiyama F; Honma N; Rank F
    Mol Oncol; 2009 Jun; 3(3):220-37. PubMed ID: 19393583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histologic spectrum of apocrine breast proliferations: a comparative study of morphology and DNA content by image analysis.
    Raju U; Zarbo RJ; Kubus J; Schultz DS
    Hum Pathol; 1993 Feb; 24(2):173-81. PubMed ID: 8381766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients.
    Fuehrer N; Hartmann L; Degnim A; Allers T; Vierkant R; Frost M; Visscher D
    Arch Pathol Lab Med; 2012 Feb; 136(2):179-82. PubMed ID: 22288965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases.
    Moriya T; Sakamoto K; Sasano H; Kawanaka M; Sonoo H; Manabe T; Ito J
    Mod Pathol; 2000 Jan; 13(1):13-8. PubMed ID: 10658905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.